Can Older Adults Safely Stop Taking Statins?

Can Older Adults Safely Stop Taking Statins?

CHICAGO — Older patients without cardiovascular (CV) disease may be able to safely stop statins for primary prevention, but doing so may still carry risks.In the STREAM trial, discontinuing statins was noninferior to continuing treatment for reducing CV death and risk, though major events were numerically more common in the discontinuation arm.For individuals like those enrolled in the trial, the data suggest it is “safe to stop statins,” said Nicolas Rodondi, MD, director of the Institute of Primary Health Care (BIHAM) at the University of Bern in Bern, Switzerland. The trial was presented as a late-breaker at the American Heart Association (AHA) Scientific Sessions 2026 and published simultaneously in The New England Journal of Medicine.Discontinuing May Be ‘Acceptably Safe’While not objecting to the principle that patients who understand the data might consider stopping statins, Amit Khera, MD, who was not involved in the study, offered a different perspective.Based on this study, many patients might consider stopping statins “acceptably safe,” said Khera, clinical chief of cardiology and director of the Preventive Cardiology Program at UT Southwestern Medical Center in Dallas.Citing the 2-year study outcomes, Khera focused on the fact that about 1 in 40 participants who stopped their statin had an event that could have been avoided if they had stayed on therapy. This number might be useful to clinicians and patients considering the risks and benefits of statin discontinuation, he said.The risk is not zero, but Khera suggested that a patient motivated to discontinue statins might consider the risk acceptable.In STREAM, 1880 participants aged 70 years or older on a statin for primary prevention were randomized at 24 clinical sites in three countries to discontinue or remain on statin therapy. The primary endpoint at 2 years was a composite of nonfatal myocardial infarction (MI), nonfatal ischemic stroke, or death from any cause.Data showed the between-group difference in restricted mean event-free survival time at 2 years was -2.0 weeks. The lower limit of the 95% CI was -3.7 weeks, which remained above the prespecified noninferiority margin of -5.2 weeks, thereby confirming noninferiority (P < .001).When evaluated independently, stopping vs continuing statins was also noninferior with respect to all individual components of the primary endpoint as well as CV and non-CV death. The noninferiority was preserved when evaluated by an intention-to-treat or per-protocol analysis.No Quality-of-Life ImprovementsQuality of life, as measured with the EuroQoL Group 5-dimension questionnaire, in the two groups was equivalent at the end of the 2-year follow-up.In other words, stopping statin therapy did not translate into better well-being overall from the patient perspective. There was also a lack of meaningful difference in sarcopenia or muscle weakness, as measured with the Strength, Assistance With Walking, Rise From a Chair, Climb Stairs, and Falls (SARC-F) questionnaire designed to assess patient-rated strength. The questionnaire also assesses propensity to fall as well as difficulties walking, rising from a chair, and climbing stairs. The SARC-F scores were essentially equivalent between study arms.The mean pain scores, measured on a scale of 1 to 100 by the patient, at 3 months did associate statin discontinuation with a modest numerical advantage for pain, but the finding was not significant.In addition to 2-year outcomes, Rodondi provided data on the components of the primary endpoint at 4 years.The event rates over this longer period increased in both arms of the study, but they increased more in the discontinuation arm. For example, nonfatal MIs, which occurred in fewer than 1% of patients in both arms at 2 years, had reached 1.6% and 0.6% in the discontinuation and continuation arms at 4 years, respectively. The rates of death from any cause, which diverged only slightly at 2 years, reached 9.8% and 8.0%, respectively.The AHA-invited discussant, Karen Alexander, MD, a professor of cardiology at Duke University in Durham, North Carolina, acknowledged that many older patients are interested in whether they can discontinue statins safely. She praised a randomized controlled trial that can supply data to address the question.However, she suggested that the study does not provide a yes or no answer. By the definitions of the trial, discontinuing was noninferior, but she considered the 5.2-week margin of difference after 2 years to be generous, and the evidence of a growing disadvantage for event-free survival at 4 years to be relevant when explaining the data to patients.In fact, the question of whether statins are beneficial in older patients has already been answered, according to Alexander, who cited the recent results of the STAREE trial.Presented at the 2026 European Society of Cardiology meeting and published in The New England Journal of Medicine, the double-blind, placebo-controlled STAREE trial enrolled nearly 10,000 patients over age 70. The study statin, atorvastatin, was associated with a 30% reduction in the primary CV composite endpoint of death from CV causes, nonfatal MI or stroke, or coronary revascularization (hazard ratio, 0.70; P < .001).“For a group of patients who were presumably tolerating statins when enrolled in STREAM, there did not appear to be much gain for discontinuing treatment,” said Alexander, referring to the quality-of-life data. With the exception of eliminating the cost and inconvenience of a daily therapy, “we cannot say from this trial that stopping statins has any objective benefits.”Still, she conceded that patients might reasonably elect to discontinue statins based on these data. For older patients with comorbidities who suspect statins are a source of at least some of their complaints, a trial of discontinuation might be one approach for evaluating whether their quality of life improves.At that point, patients might be in a better position to weigh risks and benefits, but any choice might be reasonable for someone well informed.“We are back to individual decision-making,” Alexander said.The STREAM trial was funded by the Swiss National Science Foundation. Rodondi and Alexander reported having no potential conflicts of interest. Disclosures for Khera could not be confirmed.Ted Bosworth, a career medical writer based in New York City, has been covering advances in clinical medicine, including cardiology, for several decades.

Original Source

Read the full article at Medscape →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.